

18. Perri GD, Cadeo GP, Castelli F, et al Transmission of HIV-associated tuberculosis to health-care workers. *Lancet* 1992;340:682.
19. Centers for Disease Control and Prevention. Probable transmission of multidrug-resistant tuberculosis in a correctional facility--California. *MMWR* 1993;42:48-51.
20. Onorato I. Tuberculosis in the United States. Multiple drug-resistant TB in the US. In: *National Workshop on Tuberculosis, HIV and Other Emerging Issues*. Ottawa, ON: Health Canada; May 3-5, 1993:2-3.
21. Styblo K. The estimation of the annual risk of tuberculosis infection. *Bull Int Union Tuberc* 1978;51(suppl):1-101.
22. Becker H. An 'outbreak' of tuberculin converters in a residential care facility. *Geriatric Medicine Quarterly* 1989;3:179,188,190-191,194-195,203.
23. Jereb JA, Elevens RM, Privett TD, et al. Tuberculosis in health care workers at a hospital with an outbreak of multidrug-resistant *Mycobacterium tuberculosis*. *Arch Intern Med* 1995;155:854-859.
24. Berman J, Levin ML, Tangerose S, Desi L. Tuberculosis risk for hospital employees: analysis of a five-year tuberculin skin-testing program. *Am J Public Health* 1981;71:1217-1222.
25. Faden HS, Lee J, Ogra PL. Employee health screening in pediatric hospital. *NY State J Med* 1979;79:1708-1711.
26. Statistics Canada. *Tuberculosis Statistics, 1992*. Ottawa, ON: Statistics Canada; 1994 (Catalogue no. 82-220).
27. Ontario Ministry of Health. Epidemiology of tuberculosis in Ontario, 1989-1992. *Public Health and Epidemiology Report*. Public Health Branch, Ontario Ministry of Health; 1994;5(3):63-72.
28. Bailey TC, Fraser VJ, Spitznagel EL, Dunagan WC. Risk factors for a positive tuberculin skin test among employees of an urban, midwestern teaching hospital. *Ann Intern Med* 1995;122:580-585.
29. Moline JM, Markowitz SB. Medical surveillance for workers exposed to tuberculosis. *Occup Med* 1994;9(4):695-721.
30. Ada1 KA, Anglim AM, Palumbo CL, Titus MG, Coyner BJ, Farr BM. The use of high-efficiency particulate respirators to protect hospital workers from tuberculosis: a cost-effectiveness analysis. *N Engl J Med* 1994;331:169-173.
31. Nettleman MD, Fredrickson M, Good NL, Hunter SA. Tuberculosis control strategies: the cost of particulate respirators. *Ann Intern Med* 1994;121:37-40.
32. Fanning EA, Menzies R. Surveillance of medical students for TB urged. *Can Med Assoc J* 1995;152:328. Letter.

Fluoroquinolone for *E coli* in Poultry

by **Gina Pugliese, RN, MS**
Medical News Editor

The US Food and Drug Administration (FDA) has approved a water-soluble form of sarafloxacin hydrochloride for the treatment of *Escherichia coli* infections in flocks of chickens and turkeys raised for food.

This is the first time any fluoroquinolone has been approved for animal use in the United States. The FDA is limiting distribution to areas of the country with intensive poultry farming.

The Centers for Disease Control and Prevention will add antibiotic susceptibility testing to its surveillance of

E coli O157:H7 and *Salmonella* in five states. If fluoroquinolone-resistant bacteria arise, a federal interagency group will oversee the use of molecular methods to trace the origins and spread of the resistant bacteria.

FROM: Gough M. FDA approves fluoroquinolone for use in poultry. *Lancet* 1995;346:960.